Af­ter ran­corous threats and a clin­i­cal hold, Ap­plied Ther­a­peu­tics is set to re­sume pe­di­atric galac­tosemia study

Af­ter an anony­mous re­port raised red flags over Ap­plied Ther­a­peu­tics’ in­tegri­ty in Ju­ly, say­ing the com­pa­ny “cher­ry picked” da­ta and os­ten­si­bly prompt­ing a short at­tack, the biotech ac­cused the au­thors of the re­port of fraud and threat­ened le­gal ac­tion. Then, a month lat­er, the FDA in­di­cat­ed it al­so had con­cerns over its lead galac­tosemia pro­gram, slap­ping a clin­i­cal hold on a study test­ing their can­di­date in chil­dren.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER